Varenicline:? An a4ß2 Nicotinic ReceptorPartial Agonist for Smoking Cessation

Autor: Coe, Jotham W., Brooks, Paige R., Vetelino, Michael G., Wirtz, Michael C., Arnold, Eric P., Huang, Jianhua, Sands, Steven B., Davis, Thomas I., Lebel, Lorraine A., Fox, Carol B., Shrikhande, Alka, Heym, James H., Schaeffer, Eric, Rollema, Hans, Lu, Yi, Mansbach, Robert S., Chambers, Leslie K., Rovetti, Charles C., Schulz, David W., Tingley, F. David, O'Neill, Brian T.

Publikováno v: Journal of Medicinal Chemistry; January 2005, Vol. 48 Issue: 10 p3474-3477, 4p

Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.

Autor: Coe JW; Pfizer Global Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, USA. jwcoe@pfizer.com, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, Sands SB, Davis TI, Lebel LA, Fox CB, Shrikhande A, Heym JH, Schaeffer E, Rollema H, Lu Y, Mansbach RS, Chambers LK, Rovetti CC, Schulz DW, Tingley FD 3rd, O'Neill BT

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2005 May 19; Vol. 48 (10), pp. 3474-7.